Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.72 |
| ▸ | LCK | P06239 | 15/20 | 0.72 |
| ▸ | BTK | Q06187 | 12/20 | 0.72 |
| ▸ | EGFR | P00533 | 9/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946806 | 1.00 | JAK3 (0.72) | JAK3LCKBTKEGFR | |
| SCHEMBL21855216 | 1.00 | JAK3 (0.72) | JAK3LCKBTKEGFR | |
| SCHEMBL25503760 | 0.91 | JAK3 (0.69) | JAK3LCKBTKEGFR | |
| SCHEMBL21946759 | 0.89 | JAK3 (0.64) | JAK3LCKBTKEGFR | |
| SCHEMBL31039901 | 0.89 | JAK3 (0.64) | JAK3LCKBTKEGFR | |
| SCHEMBL31039881 | 0.89 | JAK3 (0.73) | JAK3LCKBTKEGFR | |
| SCHEMBL21946364 | 0.89 | JAK3 (0.73) | JAK3LCKBTKEGFR | |
| Hydrochloric Acid SCHEMBL25198852 | 0.88 | JAK3 (0.72) | JAK3LCKBTKEGFR | |
| SCHEMBL21946711 | 0.88 | JAK3 (0.72) | JAK3LCKBTKEGFR | |
| SCHEMBL24833610 | 0.85 | JAK3 (0.87) | JAK3LCKBTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113412259-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |